Literature DB >> 29167393

What evidence do we need for biomarker qualification?

Chris Leptak1, Joseph P Menetski2, John A Wagner3, Jiri Aubrecht4, Linda Brady5, Martha Brumfield6, William W Chin7, Steve Hoffmann2, Gary Kelloff8, Gabriela Lavezzari9, Rajesh Ranganathan10, John-Michael Sauer6, Frank D Sistare11, Tanja Zabka12, David Wholley13.   

Abstract

Biomarkers can facilitate all aspects of the drug development process. However, biomarker qualification-the use of a biomarker that is accepted by the U.S. Food and Drug Administration-needs a clear, predictable process. We describe a multistakeholder effort including government, industry, and academia that proposes a framework for defining the amount of evidence needed for biomarker qualification. This framework is intended for broad applications across multiple biomarker categories and uses.
Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Mesh:

Substances:

Year:  2017        PMID: 29167393     DOI: 10.1126/scitranslmed.aal4599

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  21 in total

Review 1.  Remote Cardiac Safety Monitoring through the Lens of the FDA Biomarker Qualification Evidentiary Criteria Framework: A Case Study Analysis.

Authors:  Elena S Izmailova; William A Wood; Qi Liu; Vadim Zipunnikov; Daniel Bloomfield; Jason Homsy; Steven C Hoffmann; John A Wagner; Joseph P Menetski
Journal:  Digit Biomark       Date:  2021-04-22

2.  Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.

Authors:  Ann Chen Wu; James P Kiley; Patricia J Noel; Shashi Amur; Esteban G Burchard; John P Clancy; Joshua Galanter; Maki Inada; Tiffanie K Jones; Jonathan A Kropski; James E Loyd; Lawrence M Nogee; Benjamin A Raby; Angela J Rogers; David A Schwartz; Don D Sin; Avrum Spira; Scott T Weiss; Lisa R Young; Blanca E Himes
Journal:  Am J Respir Crit Care Med       Date:  2018-12-15       Impact factor: 21.405

3.  Biomarkers of Chronic Renal Tubulointerstitial Injury.

Authors:  Serena M Bagnasco; Avi Z Rosenberg
Journal:  J Histochem Cytochem       Date:  2019-06-26       Impact factor: 2.479

4.  BIOMARKERS AND NEUROBEHAVIORAL DIAGNOSIS.

Authors:  Joshua B Ewen; William Z Potter; John A Sweeney
Journal:  Biomark Neuropsychiatry       Date:  2021-01-04

5.  Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth.

Authors:  Romuald Girard; Hussein A Zeineddine; Janne Koskimäki; Maged D Fam; Ying Cao; Changbin Shi; Thomas Moore; Rhonda Lightle; Agnieszka Stadnik; Kiranj Chaudagar; Sean Polster; Robert Shenkar; Ryan Duggan; David Leclerc; Kevin J Whitehead; Dean Y Li; Issam A Awad
Journal:  Circ Res       Date:  2018-05-02       Impact factor: 17.367

6.  Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases.

Authors:  Gerard Honig; Caren Heller; Andrés Hurtado-Lorenzo
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

Review 7.  Animal Models Reflecting Chronic Obstructive Pulmonary Disease and Related Respiratory Disorders: Translating Pre-Clinical Data into Clinical Relevance.

Authors:  Lloyd Tanner; Andrew Bruce Single
Journal:  J Innate Immun       Date:  2019-09-17       Impact factor: 7.349

Review 8.  Metabolomics in chronic pain research.

Authors:  Shweta Teckchandani; G A Nagana Gowda; Daniel Raftery; Michele Curatolo
Journal:  Eur J Pain       Date:  2020-11-05       Impact factor: 3.931

Review 9.  Qualification of translational safety biomarkers.

Authors:  John-Michael Sauer; Amy C Porter
Journal:  Exp Biol Med (Maywood)       Date:  2021-03-23

10.  Perspectives on statistical strategies for the regulatory biomarker qualification process.

Authors:  Suzanne B Hendrix; Robin Mogg; Sue Jane Wang; Aloka Chakravarty; Klaus Romero; Samuel P Dickson; John-Michael Sauer; Lisa M McShane
Journal:  Biomark Med       Date:  2021-05-26       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.